Search Results

In summary, our study shows that inhibiting homodimerization has a setmelanotide-like effect on Gq/11

October 2022 Increased Anxiety-like Behaviors in Adgra1-/- Male But Not Female Mice are Attributable

Cholesterol bound to the amino-terminal permease-like region of LYCHOS, and mutating this site impaired

October 2022 Mechanism of enhanced sensitivity of mutated β-adrenergic-like octopamine receptor to amitraz Previous assays verified that a typical G protein-coupled receptor, β-adrenergic-like octopamine receptor

September 2022 "The glucagon-like peptide-1 receptor (GLP-1R) plays a key role in metabolism and is an

September 2022 A2B Adenosine Receptor Enhances Chemoresistance of Glioblastoma Stem-Like Cells under and the presence of a cell subpopulation that persists under hypoxic niches, called glioblastoma stem-like

Activation of the proton-sensing GPCR, GPR65 on fibroblast-like synoviocytes contributes to inflammatory joint pain Luke A Pattison , Rebecca H Rickman , Graham Ladds , Ewan St John Smith , et al. Biologist GPCR Activation and Signaling Activation of the proton-sensing GPCR, GPR65 on fibroblast-like

Toll-like receptor 4 (TLR4) is one such non-GPCR receptor, which involves MyD88-dependent and TRIF-dependent

cell-induced inflammation "Gut intraepithelial lymphocytes (IELs) are thought to calibrate glucagon-like

. 👉 What it looks like in real life: Meetings end with explanations, not decisions BD calls “went great in the CEO’s brain or slide decks that haven’t been touched in months 👉 From the inside, it feels like From the outside, it looks like ambiguity. Strategic Takeaway - Why Traction Slips Scientific isolation doesn’t feel like a mistake. It feels like focus.

silico identification of a biarylamine acting as agonist at human β3 adrenoceptors and exerting BRL37344-like malformations by endothelial activating GPR4 signals GPCRs in Neuroscience Involvement of a silkworm D2-like Development DKK 25 million to development of databases supporting medical research ‘Define your own success’: Duke

Serafini described his connection to GPCRs as tangential but inevitable: "I feel like I never was particularly intriguing because it was expressed robustly both in the peripheral nervous system and in central circuits like highlighted that in modern pain drug development, the field has remained too focused on ion channels like downstream cascade is probably a little bit weaker than if you were hitting a GPCR... and honestly, like

👉 In early-stage biotech, activity often feels like strategy. On the surface, this looks like a strength. There is movement across the board. Internally, this feels like diversification. Externally, especially in biotech fundraising, it feels like hesitation. Letting go of a program can feel like abandoning potential value.

Instead of saying, “This looks like partial agonism” , you can ask: What happens if concentration increases Without the right model, it’s like staring at identical twins—you can’t tell them apart until you see Without a framework, this looks like an assay error. What looked like four conflicting behaviors turned out to be one coherent mechanism , hidden in plain a shift,” “seems like baseline activation”—you’re leaving risk on the table.

If you’re applying orthosteric logic to modulator-driven systems, you’re likely misreading your assays—and You’ll learn how to recognize these shifts using vivid analogies (like Bruce Wayne vs. Kenakin shows how even small cooperativity values (like α = 0.1) cap the shift in signal . The takeaway:  what looks like pharmacology failure may be a systems problem . If you’re still using orthosteric assumptions to interpret allosteric binding data, you're likely missing

Through real-world examples (like 5-HT2A and CCR5 agonists), Terry shows how slow-onset agonists can Because when true pharmacological profiling is essential—like detecting partial or inverse agonism—calcium

This approach reflects his focus on developing models that behave  like patients before molecular exploration hypothesis, Serafini’s team noticed that hamsters infected with SARS-CoV-2 exhibited persistent pain-like He also integrates concepts like sex differences , epigenetic inheritance , and neuroimmune crosstalk

Like many young scientists, she explored different paths and gained industry experience before realizing The work no longer felt like an assignment—it felt like a calling. “I really like academia. about having the freedom to pursue questions that matter—questions tied to urgent public health crises like

significant attention in drug discovery, especially in the context of G protein-coupled receptors (GPCRs) like the glucagon-like peptide-1 receptor (GLP-1R). As our understanding of the molecular basis of biased agonism continues to grow, it is likely to play Drucker, D.J., Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.   AZIETAKU, J.T., Profiling Glucagon-Like Peptide -1 Receptor Transducer Coupling, Signalling and Biased

In this case, we would like to focus on the synthesis of fluorescent probes. has several advantages: it is usually very robust, good yields, reagents are found in most chem labs (like Not only do they work in aqueous medium, but also in aprotic solvents like DMF, where you will need to It also poses some disadvantages – just like acid-amine amide coupling, some byproducts are obtained

Breakthroughs this week: Glucagon-like Peptide-1 Receptor (GLP-1R) Signaling; Proximity-Dependent Proteomics He shares his journey into computational chemistry and offers a compelling look at how tools like AlphaFold Harness the power of AI:  Discover how breakthroughs like AlphaFold are making previously "undruggable " targets, like olfactory receptors, accessible for computational analysis. Connect with experts:  Join a community of like-minded field-experts dedicated to improving our collective

In a field like GPCR research (where data complexity and failure rates are high), scientific rigor thrives Alkermes didn’t just improve drug screening outcomes, it redefined what great leadership in biotech looks like

. 👉 What it usually looks like: Weekly priorities shift based on whoever raised the loudest concern. investor messaging drifts Timelines become aspirational rather than operational ✅ What “good” looks like teams working with partial context narrative inconsistency across stakeholders ✅ What “good” looks like , not momentum Scientific surprises hit harder because the system has no buffer ✅ What “good” looks like

While GPCRs can exist as monomers, some types, like class C GPCRs, are obligate dimers, either as homodimers For example, dimerization has been shown to affect signaling pathways in class A dopamine receptors like Research using techniques like bioluminescence resonance energy transfer (BRET) and fluorescence resonance Graaf, C., et al., Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March Schelshorn, D., et al., Lateral allosterism in the glucagon receptor family: glucagon-like peptide 1

This was the moment when photopharmacology felt like the future. The literature was buzzing. For metabolic GPCRs (like GLP-1 and GIP receptors): Drug efficacy depends on which cells express the And importantly, they liked working together.

Complexity feels like progress. At this stage, failure does not look like failure. It looks like motion. Additional data feels like risk reduction, even when it does not change the strategic picture. Teams are no longer sure what success looks like. 👉 No single decision breaks the company, but the absence

. 👉 Most founders don’t even realize they’re still running their company like an academic research group Founders who keep operating like researchers often create internal confusion. Leadership isn’t in your lab notebook; it’s in how you decide     How to Know If You're Still Leading Like And if your thinking is still shaped by academic norms, your startup will keep running like a lab, not

For Early-Career Scientists: Your pivotal moment might not feel like fireworks. For innovators and biotech strategists, stories like Michelle’s reveal how scientific leadership emerges For GPCR research, leaders like Michelle are showing what happens when we follow the signal all the way

If the maximal response drops, non-competitive seems like the obvious answer. Terry also explores the experimental constraints —like timing and equilibrium—that determine whether He challenges the idea that curve shape alone is diagnostic, pointing out how features like receptor

These sites don’t behave like traditional active sites. Why “Affinity Alone” Isn’t Enough—Again Just like binding kinetics require us to go beyond static Kd Terry’s Pharmacology Corner  delivers trusted, razor-sharp insight to help drug discovery professionals like